AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2026
Jan 6, 2026
32254_dirs_2026-01-06_5c4472f9-cea4-4686-8018-85897c956e73.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2026-01-02
Reporting Person: Ribeiro Ramiro (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-03 | Common Stock | M | 19667.00 | $0.00 | Acquired | 19667.00 | Direct |
| 2026-01-03 | Common Stock | F | 6373.00 | $17.48 | Disposed | 13294.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | Restricted Stock Units | $0.00 | A | 85700.00 | Acquired | Common Stock (85700.00) | Direct | |
| 2026-01-02 | Stock Option (Right to Buy) | $17.48 | A | 171400.00 | Acquired | 2036-01-02 | Common Stock (171400.00) | Direct |
| 2026-01-03 | Restricted Stock Units | $0.00 | M | 19667.00 | Disposed | Common Stock (19667.00) | Direct |
Footnotes
F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
F2: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027.
F3: The option to purchase will vest and become exercisable as follows: 25% at January 2, 2027 and the remainder ratably, on a monthly basis, over the remaining three years.
F4: The restricted stock units vest in three ratable annual installments beginning January 3, 2026.